High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population.

摘要: Epidermal growth factor receptor (EGFR) exon 18-21 mutations were shown to be highly predictive of response gefitinib (Iressa) therapy in lung cancer. Studies on Western and Japanese cancers have indicated substantial differences the EGFR mutation frequency between these populations. To investigate prevalence another distinct ethnic group, alterations studied 47 consecutive non small cell from Saudi Arabia by immunohistochemistry, fluorescence situ hybridization, DNA sequencing. Detectable expression was seen 69.8% 43 interpretable cancers. amplification, present 15.3% 39 analyzable cancers, strongly associated with high levels (P = .0047). Only 1 among 34 that could successfully sequenced. It is concluded are rare Middle East patients cancer occur a similar range as patients. The remarkable rate gene amplifications potentially facilitate studies role copy number changes for anti-EGFR therapies patient sets.